140 related articles for article (PubMed ID: 35782987)
1.
Tan Y; Lo SH
Genes Dis; 2022 May; 9(3):814-819. PubMed ID: 35782987
[TBL] [Abstract][Full Text] [Related]
2. The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity.
Basak P; Dillon R; Leslie H; Raouf A; Mowat MR
BMC Cancer; 2015 Sep; 15():630. PubMed ID: 26353792
[TBL] [Abstract][Full Text] [Related]
3. Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression.
Sánchez-Martín D; Otsuka A; Kabashima K; Ha T; Wang D; Qian X; Lowy DR; Tosato G
J Natl Cancer Inst; 2018 Apr; 110(4):390-399. PubMed ID: 29202196
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of DLC1 in endothelial cells compromises the angiogenesis process.
Shih YP; Yuan SY; Lo SH
Cancer Lett; 2017 Jul; 398():46-51. PubMed ID: 28408355
[TBL] [Abstract][Full Text] [Related]
5. DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis.
Ritchey L; Ha T; Otsuka A; Kabashima K; Wang D; Wang Y; Lowy DR; Tosato G
Oncogene; 2019 Nov; 38(45):7046-7059. PubMed ID: 31409902
[TBL] [Abstract][Full Text] [Related]
6. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587
[TBL] [Abstract][Full Text] [Related]
7. DLC1 negatively regulates angiogenesis in a paracrine fashion.
Shih YP; Liao YC; Lin Y; Lo SH
Cancer Res; 2010 Nov; 70(21):8270-5. PubMed ID: 20861185
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.
Ravi A; Kaushik S; Ravichandran A; Pan CQ; Low BC
J Biol Chem; 2015 Feb; 290(7):4149-62. PubMed ID: 25525271
[TBL] [Abstract][Full Text] [Related]
9. Combination of dihydroartemisinin and resveratrol effectively inhibits cancer cell migration
Gao J; Ma F; Wang X; Li G
Food Funct; 2020 Nov; 11(11):9573-9584. PubMed ID: 33150340
[TBL] [Abstract][Full Text] [Related]
10. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Zhou X; Yang XY; Popescu NC
Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
[TBL] [Abstract][Full Text] [Related]
12. DLC1 is a direct target of activated YAP/TAZ that drives collective migration and sprouting angiogenesis.
van der Stoel M; Schimmel L; Nawaz K; van Stalborch AM; de Haan A; Klaus-Bergmann A; Valent ET; Koenis DS; van Nieuw Amerongen GP; de Vries CJ; de Waard V; Gloerich M; van Buul JD; Huveneers S
J Cell Sci; 2020 Feb; 133(3):. PubMed ID: 31964713
[TBL] [Abstract][Full Text] [Related]
13. SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions.
Tripathi BK; Anderman MF; Qian X; Zhou M; Wang D; Papageorge AG; Lowy DR
J Cell Biol; 2019 Sep; 218(9):3060-3076. PubMed ID: 31308216
[TBL] [Abstract][Full Text] [Related]
14. DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis.
Zhou X; Zimonjic DB; Park SW; Yang XY; Durkin ME; Popescu NC
Int J Oncol; 2008 Jun; 32(6):1285-91. PubMed ID: 18497990
[TBL] [Abstract][Full Text] [Related]
15. DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.
Tripathi V; Popescu NC; Zimonjic DB
Oncogene; 2014 Feb; 33(6):724-33. PubMed ID: 23376848
[TBL] [Abstract][Full Text] [Related]
16. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
[TBL] [Abstract][Full Text] [Related]
17. Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.
Gökmen-Polar Y; True JD; Vieth E; Gu Y; Gu X; Qi GD; Mosley AL; Badve SS
PLoS One; 2018; 13(10):e0204658. PubMed ID: 30278072
[TBL] [Abstract][Full Text] [Related]
18. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.
Ko FC; Ping Yam JW
Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040
[TBL] [Abstract][Full Text] [Related]
19. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1.
Sanchez-Solana B; Wang D; Qian X; Velayoudame P; Simanshu DK; Acharya JK; Lowy DR
Mol Cancer; 2021 Nov; 20(1):141. PubMed ID: 34727930
[TBL] [Abstract][Full Text] [Related]
20. The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer.
Sabbir MG; Prieditis H; Ravinsky E; Mowat MR
PLoS One; 2012; 7(7):e40302. PubMed ID: 22792269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
